A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease(SSc-ILD)
A study for patients with Systemic Sclerosis associated with Interstitial Lung Disease using study drug nintedanib
Sponsor: Boehringer Ingelheim
Enrolling: Male and Female Patients
IRB Number: AAAQ1310
Contact: Nina Patel: 212-342-6924 / np2199@cumc.columbia.edu
Additional Study Information: This study is for patients with systemic sclerosis (SSc) and associated Interstitial Lung Disease. Systemic sclerosis or systemic scleroderma is a disease that causes thickening of the skin and the internal organs which often includes the kidneys, heart, lungs and gastrointestinal tract. Your disease affects the skin but also it affects the lungs. As the lung tissue becomes more thick and scarred, your lungs lose their ability to move oxygen into your bloodstream. The purpose of this study is to investigate how well the treatment with the study drug called nintedanib can demonstrate a slowing of the rate of lung scarring (or fibrosis) and how well the study treatment has an effect on the skin thickening as well as investigate the safety of nintedanib and how well the body tolerates the drug. Patients will either be assigned the study drug or given a placebo. A placebo is a substance that looks like the study drug but contains no active drug.
This study is closed
Nina Patel, MD
Do You Qualify?
Do you have systemic sclerosis (SSc) and associated Interstitial Lung Disease? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Nina Patel